To develop and commercialise pioneering neuroscience treatments Novartis has entered into a global collaboration with Amgen to commercialise and develop…
Novartis Foundation’s new leprosy contact tracing programme launched in five countries
The approval was based on two randomised, double-blinded, placebo-controlled trials enrolling paediatric patients with chronic ITP The US Food and…
To develop treatments for MS and other autoimmune indications
Sandoz India’s Turbhe plant to down shutters by December 2016
Novartis is increasingly confident about the potential of its new injectable drug Cosentyx, as fresh clinical data confirms its long-term…
To simplify treatment administration for patients with chronic iron overload
Britain will become the first country in the world to have a nationwide vaccination programme for the potentially deadly childhood…
Patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck &…
Acquires certain oncology products and pipeline compounds from GSK
Fortune magazine has announced its list of 2015 ‘World’s Most Admired Companies.’ The companies on the world’s most admired list…
Net sales of the pharmaceuticals business grew by 1.2 per cent during the quarter ended December 31, 2014
During the quarter under review, profit before tax was Rs 4.4 crore as against Rs 21.6 crore in the previous…
Opposing the miscellaneous petition by Wockhardt at the Intellectual Property Appellate Board (IPAB) seeking filing of additional documents, Novartis…
Oncology, autoimmune and infectious diseases/vaccines are areas for novel therapeutics and in vitro diagnostics in 2015
Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as…
Novartis has approved the sale of its OTC Division to GlaxoSmithKline Consumer for Rs 1097.3 million. It may be noted…
To explore making medicines and drug discovery tools with CRISPR genome editing technology